Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Ipsen appoints executive vice president

Ipsen SA, a specialty-driven pharmaceutical company, has appointed Francois Garnier as executive vice president and general counsel for the group, effective January 5, 2015.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Eli Lilly receives FDA approval for non-small cell lung cancer drug

Eli Lilly and Company has received its third FDA approval for CYRAMZA, which is indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer, or NSCLC, with disease progression on or after platinum-based chemotherapy.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Bayer HealthCare files BLA for hemophilia A drug with FDA

Bayer HealthCare has filed a biologics license application, or BLA, with the FDA seeking approval for BAY 81-8973, a recombinant Factor VIII compound, for the treatment of hemophilia A in adults and children.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Amedisys names president and CEO

Amedisys, Inc., a home health and hospice company, has named Paul Kusserow as president and CEO and member of the board of directors.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

WellCare names senior vice president, chief legal and administrative officer

WellCare Health Plans, Inc., a provider of managed care services, has named Blair Todt to the newly created position of senior vice president, chief legal and administrative officer and secretary.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Diabetizer uses IBM's Bluemix to build new cloud-based diabetic care app

International Business Machines Corporation, or IBM, has announced that Diabetizer, a German -based healthcare technology company, is using IBM's open platform-as-a-service, Bluemix, to build and deploy a cloud-based application that enhances care for diabetes patients around the world.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Kaiser Permanente opens new replacement hospital at Redwood City Medical Center

Kaiser Permanente, a managed care company, has opened a new replacement hospital at its Redwood City Medical Center, in Northern California.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

Isis Pharmaceuticals initiates Phase I/II myotonic dystrophy type 1 study

Isis Pharmaceuticals, Inc., a biotechnology company, has initiated a Phase I/II study for ISIS-DMPKRx in patients with myotonic dystrophy type 1, or DM1.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

OncoGenex completes patient enrollment in Phase II pancreatic cancer trial

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has completed the patient enrollment in the Rainier clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase II trial evaluating apatorsen in combination with ABRAXANE and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Published By MarketLine
18 Dec 2014
NewsWire
NewsWire

DURECT and Santen sign license agreement for ophthalmology drug

DURECT Corporation, a specialty pharmaceutical company, has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER technology to deliver an ophthalmology drug.

Published By MarketLine
18 Dec 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.